COMMON LIGHT CHAIN MOUSE
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
1 .- 26 . (canceled)
27 . A genetically modified mouse that is homozygous or heterozygous in its germline genome for a single rearranged human immunoglobulin kappa light chain variable region sequence comprising a human Vκ gene segment and a human Jκ gene segment,
wherein the genetically engineered mouse lacks endogenous immunoglobulin Vκ and/or Jκ gene segments that are capable of rearranging to form an endogenous immunoglobulin light chain variable region sequence,
wherein all immunoglobulin kappa light chains expressed by B cells of the genetically modified mouse comprise human immunoglobulin kappa light chain variable domains that are expressed from the single rearranged human immunoglobulin kappa light chain variable region sequence or a somatically hypermutated version thereof,
wherein the germline genome of the genetically modified mouse includes one or more unrearranged human V H gene segments, one or more unrearranged human D gene segments, and one or more unrearranged human J H gene segments that are operably linked to a murine C H region, and
wherein the genetically modified mouse includes at least one B cell that expresses an antibody including an immunoglobulin kappa light chain and an immunoglobulin heavy chain comprising a human immunoglobulin heavy chain variable domain expressed from a human immunoglobulin heavy chain variable region sequence that includes a V H 3-49, V H 3-66, V H 4-28, V H 4-61, or a somatically hypermutated variant thereof.
28 . The genetically modified mouse of claim 27 , wherein the human immunoglobulin heavy chain variable region sequence further comprises a D1-14, D1-20, D2-2, D2-21, D4-4, D4-11, D4-17, D4-23, D5-18, D5-24, D6-19, D6-25, or a somatically hypermutated variant thereof.
29 . The genetically modified mouse of claim 27 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is a Vκ1-39/Jκ sequence.
30 . The genetically modified mouse of claim 29 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is a Vκ1-39/Jκ5 sequence.
31 . The genetically modified mouse of claim 30 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence has a nucleotide sequence as set forth in nucleotides 2362 through 2686 of SEQ ID NO: 1.
32 . The genetically modified mouse of claim 27 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is a Vκ3-20/Jκ1 sequence.
33 . The genetically modified mouse of claim 32 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is a Vκ3-20/Jκ1 sequence.
34 . The genetically modified mouse of claim 33 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence has a nucleotide sequence as set forth in nucleotides 2373 through 2697 of SEQ ID NO: 11.
35 . The genetically modified mouse of claim 27 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence has been inserted into the germline genome of the genetically modified mouse at an endogenous mouse κ immunoglobulin light chain variable region locus.
36 . The genetically modified mouse of claim 27 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is positioned in the germline genome so that it replaces all functional endogenous mouse κ immunoglobulin light chain variable region gene segments.
37 . The genetically modified mouse of claim 27 , wherein the single rearranged human immunoglobulin kappa light chain variable region sequence is operably linked to a murine Cκ sequence.
38 . The genetically modified mouse of claim 37 , wherein the murine Cκ sequence is an endogenous mouse Cκ sequence.
39 . The genetically modified mouse of claim 27 , wherein the one or more unrearranged human V H gene segments comprises V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-33, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 4-28, V H 4-31, V H 4-34, V H 4-39, V H 4-59, V H 4-61, V H 5-51, V H 6-1, or a combination thereof.
40 . The genetically modified mouse of claim 39 , wherein the one or more unrearranged human D gene segments comprises D1-1, D1-7, D1-14, D1-20, D1-26, D2-2, D2-8, D2-15, D2-21, D3-3, D3-9, D3-10, D3-16, D3-22, D4-4, D4-11, D4-17, D4-23, D5-5, D5-12, D5-18, D5-24, D6-6, D6-13, D6-19, D6-25, D7-27, or a combination thereof.
41 . The genetically modified mouse of claim 27 , wherein in the murine C H is rat C H .
42 . The genetically modified mouse of claim 27 , wherein the murine C H is a mouse C H .
43 . An isolated cell of the mouse of claim 27 .
44 . The cell of claim 43 , wherein the cell is a B cell that expresses an antibody including an immunoglobulin kappa light chain variable domain and a human immunoglobulin heavy chain variable domain expressed from a human immunoglobulin heavy chain variable region sequence that includes a V H 3-49, V H 3-66, V H 4-28, V H 4-61, or a somatically hypermutated variant thereof.
45 . A hybridoma made with the B cell of claim 44 .